EZH2 Inhibitors Sensitize Breast Cancer to HER2 Kinase Inhibitors through Cooperative Effects on YAP and Proapoptotic Regulators
The combination of EZH2 inhibitors and HER2 kinase inhibitors potently induces tumor regression in HER2+ tumors through effects on YAP and proapoptotic proteins, providing a promising therapeutic strategy for breast cancer.
Authors
- Karen Cichowski (ORCID: https://orcid.org/0000-0003-3940-3782)
- Naiara Perurena (ORCID: https://orcid.org/0000-0003-0874-3389)
- Marina Watanabe (ORCID: https://orcid.org/0000-0003-2012-1953)
- Alexandra Indeglia (ORCID: https://orcid.org/0000-0001-9035-4969)
- Amy E. Schade (ORCID: https://orcid.org/0000-0002-0342-8251)
- Yoona Yang (ORCID: https://orcid.org/0000-0002-7446-8816)
- W. Ted Brown
- Simon Knott (ORCID: https://orcid.org/0000-0002-4018-7653)
- Akiko Yoshinaga
- Elizabeth Y. Luo
- Rhea Sahu
- Alycia Gardner
Institutions
- Cedars-Sinai Medical Center (US)
- Brigham and Women's Hospital (US)
- Harvard University (US)
Publication Details
- Journal
- Cancer Research
- Published
- 2026-01-05
- DOI
- https://doi.org/10.1158/0008-5472.can-24-3113
- Primary Topic
- Hippo pathway signaling and YAP/TAZ
- Type
- article
- Field-Weighted Citation Impact
- 0.00